Loading
Life sciences · Phase 1 Trial
ClinicalTrials.gov · September 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07113691). This is a study registration, not published results. Lead sponsor: Yale University. Recruitment status: RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 15 participants (ESTIMATED). Conditions: Extensive Stage Small Cell Lung Cancer (ES-SCLC). Interventions: DRUG: Iadademstat; DRUG: Atezolizumab; RADIATION: SBRT. Primary outcome measures: Frequency of Dose-Limiting Toxicities (DLTs) in patients treated with iadademstat combined with atezolizumab and SBRT , 35 days post the first dose of study drug on Cycle 1 Day 1, each cycle is 28 days long; Rate of Dose-Limiting Toxicities (DLTs) in patients treated with iadademstat combined with atezolizumab and SBRT , 35 days post the first dose of study drug on Cycle 1 Day 1, each cycle is 28 days long; Grade of Dose-Limiting Toxicities (DLTs) in patients treated with iadademstat combined with atezolizumab and SBRT , 35 days post the first dose of study drug on Cycle 1 Day 1, each cycle is 28 days long; Frequency of Adverse Events (AEs) in patients treated with iadademstat combined with atezolizumab and SBRT , 35 days post the first dose of study drug on Cycle 1 Day 1, each cycle is 28 days long; Rate of Adverse Events (AEs) in patients treated with iadademstat combined with atezolizumab and SBRT , 35 days post the first dose of study drug on Cycle 1 Day 1, each cycle is 28 days long; Grade of Adverse Events (AEs) in patients treated with iadademstat combined with atezolizumab and SBRT , 35 days post the first dose of study drug on Cycle 1 Day 1, each cycle is 28 days long. Brief summary: This is a phase 1b dose escalation, open-label, non-randomized study of participants with residual, progressive or recurrent ES-SCLC who previously received platinum-based chemotherapy with or without immune checkpoint inhibitor therapy; participants who have achieved only stable disease at the completion of initial platinum-based treatment are eligible for enrollment.